Thermo Fisher presented multicenter validation data for its Oncomine Comprehensive Assay Plus on the automated Ion Torrent Genexus system at AMP, arguing the amplicon‑based CGP can deliver results in about 24 hours with minimal hands‑on time. Company scientists cited high success rates with lower sample input and a 96.6% sequencing success benchmark from earlier multicenter studies. The assay covers 517 genes and complex signatures (TMB, MSI) and was previously run on GeneStudio; on Genexus, Thermo Fisher highlighted ~20 minutes of hands‑on time and next‑day reporting as solutions to lab bottlenecks. Thermo Fisher executives framed automation as a response to labor constraints in molecular pathology and genomic diagnostics. Faster CGP with automated workflows could shift clinical lab purchasing decisions and trial‑site testing logistics, affecting biomarker‑driven oncology trial enrollment and community clinic access to comprehensive molecular profiling.